Specific Antigen in Serum of Patients with Colon Carcinoma

Koprowski, Hilary; Herlyn, Meenhard; Steplewski, Zenon; Sears, Henry F.

doi:10.1126/science.6163212

Cited by 531 publications

(212 citation statements)

References 3 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…1,2 Findings of high concentrations of gangliosides in the circulation of tumour-bearing hosts, [3][4][5][6][7] which fall towards normal on removal of tumour, 4,5 support this association, as does the indirect evidence that binding between a monoclonal antibody and a colon-carcinoma-associated ganglioside is inhibited by the serum of patients with this tumour. 14 To date, however, direct thin-layer-chromatographic visualisation of gangliosides isolated and purified from the plasma of patients with cancer has not shown the presence of any ganglioside which was not also detected though perhaps in lower concentrations in the plasma of healthy normal donors. For example, levels of G M3 and G D3 , prominent constituent gangliosides of normal human plasma, were slightly raised in the plasma of patients with melanoma, 5 as were those of G M3 in plasma of patients with cerebral astrocytoma.…”

Section: Discussionmentioning

confidence: 98%

Detection of a Tumour-Associated Ganglioside in Plasma of Patients With Neuroblastoma

Ladisch¹,

Wu²

1985

The Lancet

View full text Add to dashboard Cite

SummaryAn abnormal circulating ganglioside was found in patients with neuroblastoma. This ganglioside appeared as a single band by resorcinol-HCl staining of thin-layer chromatograms of purified total gangliosides isolated from as little as 1 ml of patient plasma. It is a major ganglioside of neuroblastoma tumour tissue and was present (250-1500 pmol lipid-bound sialic acid/ml) in the plasma of five patients with widespread neuroblastoma. In contrast, the ganglioside was not detected (<50 pmol/ml) in plasma samples of six patients in complete remission, nor in plasma samples of seventeen healthy children and adults. Measurement of this circulating tumourassociated ganglioside should be clinically useful in neuroblastoma, offering a new approach to the detection of tumour and the evaluation of therapy.

show abstract

Section: Discussionmentioning

confidence: 98%

Detection of a Tumour-Associated Ganglioside in Plasma of Patients With Neuroblastoma

Ladisch¹,

Wu²

1985

The Lancet

View full text Add to dashboard Cite

show abstract

“…Carbohydrate antigen 19-9 (CA19-9) is the sialylated Lewis blood group antigen originally defined by the monoclonal antibody 1116 NS 19-9 (Koprowski et al, 1979(Koprowski et al, , 1981. A radioimmunoassay was developed for this marker in 1983 (Del Villano et al, 1983), and since that time, measurement of CA19-9 levels in serum has been commonly used as an adjunct in the diagnosis of pancreatic cancer.…”

mentioning

confidence: 99%

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

et al. 2005

View full text Add to dashboard Cite

The use of serial serum measurements of the carbohydrate antigen 19-9 (CA19-9) to guide treatment decisions and serve as a surrogate end point in clinical trial design requires further validation. We investigated whether CA19-9 decline represents an accurate surrogate for survival and time to treatment failure (TTF) in a cohort of 76 patients with advanced pancreatic cancer receiving fixeddose rate gemcitabine in three separate studies. Statistically significant correlations between percentage CA19-9 decline and both overall survival and TTF were found, with median survival ranging from 12.0 months for patients with the greatest degree of biomarker decline (475%) compared with 4.3 months in those whose CA19-9 did not decline during therapy (Po0.001). Using specific thresholds, patients with X25% decline in CA19-9 during treatment had significantly better outcomes than those who did not (median survival and TTF of 9.6 and 4.6 months vs 4.4 and 1.5 months; Po0.001). Similar results were seen using both 50 and 75% as cutoff points. We conclude that serial CA19-9 measurements correlate well with clinical outcomes in this patient population, and that decline in this biomarker should be entertained for possible use as a surrogate end point in clinical trials for the selection of new treatments in this disease.

show abstract

“…The assay employs a monoclonal antibody originally raised against a human colon carcinoma cell line (SW 1116) (Koprowski et al, 1979). Elevated CA 19-9 levels have been found in the serum of patients with various gastro-intestinal carcinomas (Del Villano et al, 1983;Koprowski et al, 1981) and the results of Sears et al (1982) indicate that the CA 19-9 antigen is a new marker which can help in the diagnosis and monitoring of colorectal carcinomas.…”

mentioning

confidence: 99%

Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases

Kuusela¹,

Jalanko²,

Roberts³

et al. 1984

Br J Cancer

View full text Add to dashboard Cite

Summary The serum levels of CA 19-9 and carcinoembryonic antigen (CEA) were determined in 37 patients with benign colorectal diseases and in 111 patients with newly discovered colorectal carcinomas or clinically verified relapses. In cancer patients, the CA 19-9 level ranged from normal (0-37Uml-1) to 77,500Uml-P whereas all samples but one from patients with benign colorectal diseases had a normal value. CA 19-9 was increased in 46% and 45% of patients with an advanced (Dukes C or D) carcinoma or a verified recidive, respectively. Only one out of 26 patients (4%) with a localized (Dukes A or B) carcinoma displayed an elevated CA 19-9 level (>37Um.1-1). No clear correlation was found between the CA 19-9 and CEA levels. The sensitivity of the CA 19-9 test (36%) was poorer than that of the CEA assay (69%), but the new test was markedly more specific (97% vs 70%) than the CEA assay.

show abstract

Specific Antigen in Serum of Patients with Colon Carcinoma

Cited by 531 publications

References 3 publications

Detection of a Tumour-Associated Ganglioside in Plasma of Patients With Neuroblastoma

Detection of a Tumour-Associated Ganglioside in Plasma of Patients With Neuroblastoma

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases

Contact Info

Product

Resources

About